Avery Therapeutics Awarded NIH SBIR

Avery Therapeutics, Inc., a pre-clinical stage company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, has been awarded a $483k SBIR grant from the National Institutes of Health to develop manufacturing, cryopreservation, storage and reconstitution methods for Avery’s first product MyCardia™. Continue reading

Marni Landry of the Paradise Valley High School CREST Program Named Arizona Bioscience Educator of the Year

The Arizona Bioindustry Association has named Marni Landry, BS, M.Ed of Paradise Valley High School as the 2016 Michael A. Cusanovich Bioscience Educator of the Year in recognition of her dedication  in the classroom and her commitment  to designing  bioscience education programs and curriculum to help inspire and create tomorrow’s bioscience leaders.Continue reading

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company.Continue reading

Tech Launch Arizona Sets Performance Records in 3rd Full Year

 

The technology commercialization office of the University of Arizona, Tech Launch Arizona, reports that it had an outstanding year during FY 2016 (July 1, 2015 to June 30, 2016) and that UA inventor engagement in technology commercialization activities has attained all-time highs as evidenced by key performance indicators. In addition to technology commercialization, the Tech Parks Arizona component of TLA finished FY 2016 with record accomplishments, as well.Continue reading